ArticleFrontiers in microbiology2019
Complete Nucleotide Sequence of Plasmids of Two
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Comparative genomic analyses ofmSystems · 2026Article
- Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026Review
- Outbreak of NDM-5-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.Journal of clinical microbiology · 2023Article
- The First Report ofInfection and drug resistance · 2023Article
- Preferred β-lactone synthesis can explain high rate of false-negative results in the detection of OXA-48-like carbapenemases.Scientific reports · 2022Article
- A clinical KPC-producingFrontiers in microbiology · 2022Article
- Characterization of NDM-5 Carbapenemase-Encoding Gene (Infection and drug resistance · 2022Article
- The hazard of carbapenemase (OXA-181)-producingFrontiers in microbiology · 2022Article
- Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer.Journal of global antimicrobial resistance · 2021Article
- Emergence of oxacillinase-181 carbapenemase-producing diarrheagenicEmerging microbes & infections · 2021Article
- Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany.Antimicrobial agents and chemotherapy · 2021Article
- Genomic Characterization of VIM and MCR Co-Producers: The First Two Clinical Cases, in Italy.Diagnostics (Basel, Switzerland) · 2021Article
- Genetic Plurality of OXA/NDM-Encoding Features Characterized FromFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of this study was to genetically characterize two carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.